<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01737177</url>
  </required_header>
  <id_info>
    <org_study_id>FIL R2-B</org_study_id>
    <nct_id>NCT01737177</nct_id>
  </id_info>
  <brief_title>Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL</brief_title>
  <acronym>R2-B</acronym>
  <official_title>Bendamustine, Lenalidomide and Rituximab (R2-B) Combination as a Second-Line Therapy for First Relapsed-Refractory Mantle Cell Lymphomas: A Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter phase II trial designed to evaluate the safety and
      activity of the combination of Bendamustine, Lenalidomide and Rituximab (R2-B) in patients
      with first relapsed/refractory mantle cell lymphoma (MCL) and the efficacy and safety of a
      maintenance treatment with Lenalidomide for 18 months from the end of R2-B (from month 7 to
      24) for those responding to the induction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II study, non randomized, multicenter. Patients with MCL refractory to front
      line therapy or in first relapse will be enrolled.

      The study includes an induction phase, a consolidation phase, a maintenance phase and a
      follow up phase.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2012</start_date>
  <completion_date type="Actual">February 2, 2017</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response (CR) rate</measure>
    <time_frame>At the end of the consolidation phase (6 months)</time_frame>
    <description>Proportion of CR according to the Cheson2007 response criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maintenance Progression Free Survival (maPFS)</measure>
    <time_frame>36 months</time_frame>
    <description>maPFS will be defined in the maintenance cohort as the time between the date of CR/PR and the date of disease progression or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence of grade 3 or higher Toxicity measured by CTCAE v.4 during induction and maintenance therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>at the end of the consolidation phase (6 months)</time_frame>
    <description>ORR at the end of the consolidation treatment is defined as Complete Response(CR) or Partial Response according to the Cheson 2007 response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) in all patients</measure>
    <time_frame>42 months</time_frame>
    <description>PFS will be measured from the day of enrolment and of disease progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>36 months</time_frame>
    <description>OS will be defined as the date of enrolment and the date of recurrence/disease progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular response rate</measure>
    <time_frame>24 months</time_frame>
    <description>rate of conversion to molecular remission measured by PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular relapse rate during study period</measure>
    <time_frame>42 months</time_frame>
    <description>rate of conversion to molecular relapse measured by PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease kinetics of minimal residual disease (MRD) during study period</measure>
    <time_frame>up to 42 months</time_frame>
    <description>measured by real time PCR in the bone marrow and peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of second primary malignancies</measure>
    <time_frame>up to 42 months</time_frame>
    <description>incidence of any second primary malignancies (haematological and not haematological) diagnosed after the conclusion of induction phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the possible relationship between Cereblon expression and response to therapy</measure>
    <time_frame>6 months</time_frame>
    <description>Possible relationship between Cereblon expression and response to therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Bendamustina, Lenalidomide, Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 arm for all patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine, Lenalidomide, Rituximab</intervention_name>
    <description>INDUCTION PHASE (COURSE 1-4)
Bendamustine: 70 mg/m2 on day 2 and 3 every 28
Lenalidomide: 10 mg/daily on day 1 to 14 of a 28 days course
Rituximab: 375 mg/m2 on day 1 every 28 days; only for the first cycle in the induction phase will start on day 8
CONSOLIDATION PHASE (courses 5-6)
Patients in CR and PR at the end of the induction phase
Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days course.
Rituximab: 375 mg/m2 on day 1 every 28 days
MAINTENANCE PHASE (courses 7-24)
Patients in CR or PR at the end of the consolidation treatment with Lenalidomide until disease progression or unacceptable toxicity up to 18 months (from month 7 to month 24)
- Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days</description>
    <arm_group_label>Bendamustina, Lenalidomide, Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has a diagnosis of MCL according to the WHO classification;

          -  Patient age is ≥ 18 years;

          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2;

          -  Understands and voluntarily signs an informed consent form;

          -  Able to adhere to the study visit schedule and other protocol requirements;

          -  Patients treated with one prior regimen and relapsed, or refractory to front line
             therapy; front line consolidation with autologous stem cell transplantation is
             considered to be part of first line therapy;

          -  Patient has at least one site of measurable nodal disease at baseline ≥ 2.0 cm in the
             longest transverse diameter as determined by CT scan (MRI is allowed only if CT scan
             can not be performed). Note: Patients with bone marrow involvement are eligible;

          -  Adequate haematological counts: ANC &gt; 1.5 x 109/L and platelet count &gt; 75 x 109/L
             unless due to bone marrow involvement by MCL;

          -  Conjugated bilirubin up to 2 x ULN unless due to liver involvement by MCL;

          -  Alkaline phosphatase and transaminases up to 2 x ULN unless due to liver involvement
             by MCL;

          -  Creatinine clearance ≥ 30 ml/min; a dose reduction of Lenalidomide for patients with
             creatinine clearance ≥ 30 mL/min but &lt; 50 mL/min is planned;

          -  Written informed consent was obtained from the patient prior to any study-specific
             screening procedures;

          -  Patient has the ability to swallow capsules or tablets;

          -  Life expectancy ≥ 6 months;

          -  Disease free of prior malignancies (a part MCL) with the exception of currently
             treated basal cell, squamous cell carcinoma of the skin, or carcinoma &quot;in situ&quot; of the
             cervix or breast;

        Exclusion Criteria:

          -  Patients who have received an experimental drug or used an experimental medical device
             within 4 weeks before the planned start of treatment. Concurrent participation in
             non-treatment studies is allowed, if it will not interfere with participation in this
             study;

          -  Patient has a history of CNS involvement with lymphoma;

          -  Patients with previous history of malignancies (a part MCL) ≤ 3 years before study
             accrual with the exception of currently treated basal cell and squamous cell carcinoma
             of the skin, or carcinoma &quot;in situ&quot; of the cervix;

          -  History of clinically relevant liver or renal insufficiency; significant cardiac,
             vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic,
             hematologic, psychiatric, or metabolic disturbances;

          -  Patient has any other concurrent severe and/or uncontrolled medical condition(s)
             (e.g., uncontrolled diabetes mellitus, active or uncontrolled infection) that could
             cause unacceptable safety risks or compromise compliance with the protocol;

          -  Creatinine clearance &lt; 30 ml/min;

          -  Patient has a known history of HIV seropositivity;

          -  Patient has active HBV hepatitis. The following categories of HBV positive patients
             but with non evidence of active hepatitis may be considered for the study and treated
             with R2-B (see also Section 8.1.8):

          -  patient is HBsAg + with HBV DNA &lt; 2000 UI/ml (inactive carriers); HBV DNA &gt; 2000 UI/ml
             is criteria of exclusion;

          -  patient is HBsAg - HBsAb +;

          -  patient is HBsAg - but HBcAb +

          -  Patients with HCV active hepatitis are excluded from the study. Patient with no
             evidence of active hepatitis and/or advanced chronic liver disease according to liver
             biopsy or fibro-scan evaluation may be included into the study

          -  Patients have received previous treatment with either Bendamustine and/or
             Lenalidomide.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Zaja, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Ematologica - Udine - Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UOC Ematologia Trani</name>
      <address>
        <city>Trani</city>
        <state>Barletta-Andria-Trani (BT)</state>
        <zip>76125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST Meldola</name>
      <address>
        <city>Meldola</city>
        <state>Forlì Cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di riferimento Oncologico CRO Aviano</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS‐Centro di Riferimento Oncologico UO di Ematologia e Trapianto Cellule Staminali</name>
      <address>
        <city>Rionero in Vulture</city>
        <state>Potenza</state>
        <zip>85028</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicina Interna 2 ad indirizzo Ematologico AOU San Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <state>Torino</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ematologia AO SS. Antonio e Biagio e C. Arrigo</name>
      <address>
        <city>Alessandria</city>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica di Ematologia AOU Umberto I Ospedali Riuniti</name>
      <address>
        <city>Ancona</city>
        <zip>60100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ematologia Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Ospedale Cardarelli ASREM</name>
      <address>
        <city>Campobasso</city>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncoematologia Ospedale SS. Anna e Sebastiano</name>
      <address>
        <city>Caserta</city>
        <zip>81100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia Osp. Garibaldi Nesima</name>
      <address>
        <city>Catania</city>
        <zip>95100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pugliese Ciaccio Dipartimento oncoematologico</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica AOU San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia AOU S. Martino - IST</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia Universitaria Polo Pontino Sapienza</name>
      <address>
        <city>Latina</city>
        <zip>04100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ematologia Azienda Ospedali Riuniti Papardo Piemonte</name>
      <address>
        <city>Messina</city>
        <zip>98100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia Policlinico Universitario AOU G. Martino</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ematologia ‐ Trapianto di midollo osseo Fond. IRCCS Istituto Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ematologia AO Niguarda Cà Granda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCDU Ematologia ‐ Università del Piemonte Orientale</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia, Azienda Ospedali Riuniti Villa Sofia Cervello</name>
      <address>
        <city>Palermo</city>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Complessa di Ematologia Ospedale di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Ematologia Ospedale Civile di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia Az Ospedaliera Pisana Ospedale &quot;S.Chiara&quot;</name>
      <address>
        <city>Pisa</city>
        <zip>56100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia Ospedale Santa Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia AO Bianchi Melacrino Morelli</name>
      <address>
        <city>Reggio Calabria</city>
        <zip>89124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ematologia AO Santa Maria Nuova IRCCS</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Oncoematologia ospedale degli Infermi</name>
      <address>
        <city>Rimini</city>
        <zip>47900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Ospedale San Eugenio</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia e Trapianto Istituto Regina Elena (IFO)</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Ospedale S.Camillo Forlanini</name>
      <address>
        <city>Roma</city>
        <zip>00149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Università La Sapienza</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia AO San Giovanni Addolorata</name>
      <address>
        <city>Roma</city>
        <zip>00184</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia e Trapianti A.O. San Giovanni di DIO e Ruggi D'Aragona</name>
      <address>
        <city>Salerno</city>
        <zip>84131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Ospedale SG Moscati</name>
      <address>
        <city>Taranto</city>
        <zip>74100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Oncoematologia con autotrapianto AO Santa Maria</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ematologia - AO Città della Salute e della Scienza</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Ematologia U - AO Città della Salute e della Scienza</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica ASUI Integrata di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica Varese Ospedale di Circolo e Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia Ospedale di Circolo e Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2012</study_first_submitted>
  <study_first_submitted_qc>November 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MCL</keyword>
  <keyword>Mantle Cell Lymphoma</keyword>
  <keyword>RELAPSED-REFRACTORY</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

